<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305444</url>
  </required_header>
  <id_info>
    <org_study_id>DTRM-555_001</org_study_id>
    <nct_id>NCT04305444</nct_id>
  </id_info>
  <brief_title>Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas</brief_title>
  <official_title>Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang DTRM Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang DTRM Biopharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Targeted drug therapies have greatly improved outcomes for patients with relapsed or&#xD;
      refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However,&#xD;
      single drug therapies have limitations, therefore, the current study is evaluating a novel&#xD;
      oral combination of targeted drugs as a way of overcoming these limitations. This study will&#xD;
      determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL&#xD;
      or R/R non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted in three parts: Phase Ia, Phase Ib and Phase II,&#xD;
      disease-specific expansion cohorts. Phase Ia explored escalating doses of a monotherapy of a&#xD;
      novel Bruton's Tyrosine Kinase (BTK) inhibitor, DTRMWXHS-12. Phase Ib explored two&#xD;
      combination therapies, DTRM-505 (DTRMWXHS-12 and everolimus) and DTRM-555 (DTRMWXHS-12,&#xD;
      everolimus and pomalidomide).&#xD;
&#xD;
      The current Phase II study will further examine the investigational triple combination&#xD;
      treatment, DTRM-555 for efficacy and safety. The study is being conducted in five&#xD;
      disease-specific cohorts: Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma, Germinal&#xD;
      Center B-Cell (GCB) Diffuse Large B-Cell Lymphoma, Richter's Transformation, transformed&#xD;
      Follicular Lymphoma, and relapsed or refractory Chronic Lymphocytic Leukemia.&#xD;
&#xD;
      The Primary Objective of the Phase II study is to determine the efficacy of the triple&#xD;
      combination therapy, DTRM-555, in the five disease-specific cohorts. The Secondary Objectives&#xD;
      are (1) to determine the safety of DTRM-555 in the cohorts and (2) to obtain the&#xD;
      pharmacokinetics of DTRM-555 (i.e., DTRMWXHS-12, everolimus and pomalidomide).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients, regardless of disease-specific cohort, will receive the same dose of DTRM-555. There are two stages to the study, and there is the potential for 120 patients in total (potentially 24 patients in each of the 5 cohorts) to participate in the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Responses (CR) and Partial Responses (PR) with DTRM-555 in the five disease-specific cohorts</measure>
    <time_frame>24 months</time_frame>
    <description>Response in lymphoma patients will be assessed according to Lugano 2014 criteria guidelines for response assessment of Hodgkin and non-Hodgkin lymphoma. Response in CLL patients will be assessed according to International Workshop on CLL (iwCLL) 2018 criteria for treatment of CLL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-Emergent Adverse Events (AEs) in the five disease-specific cohorts</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of participants with Treatment-Emergent Adverse Events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) with DTRM-555 in the five disease-specific cohorts</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>Response in lymphoma patients will be assessed according to Lugano 2014 criteria guidelines for response assessment of Hodgkin and non-Hodgkin lymphoma. Response in CLL patients will be assessed according to iwCLL 2018 criteria for treatment of CLL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or blood concentration versus time profiles of DTRMWXHS-12, everolimus and pomalidomide will be evaluated to determine key pharmacokinetic parameters for the three drugs</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma or blood concentration versus time profiles of DTRMWXHS-12, everolimus and pomalidomide will be evaluated to determine Area Under the Curves (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or blood concentration versus time profiles of DTRMWXHS-12, everolimus and pomalidomide will be evaluated to determine key pharmacokinetic parameters for the three drugs</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma or blood concentration versus time profiles of DTRMWXHS-12, everolimus and pomalidomide will be evaluated to determine Maximum Observed Plasma or Blood Concentrations (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or blood concentration versus time profiles of DTRMWXHS-12, everolimus and pomalidomide will be evaluated to determine key pharmacokinetic parameters for the three drugs</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma or blood concentration versus time profiles of DTRMWXHS-12, everolimus and pomalidomide will be evaluated to determine the Times to Reach Cmax (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or blood concentration versus time profiles of DTRMWXHS-12, everolimus and pomalidomide will be evaluated to determine key pharmacokinetic parameters for the three drugs</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma or blood concentration versus time profiles of DTRMWXHS-12, everolimus and pomalidomide will be evaluated to determine Elimination Half-Lives (t1/2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Relapsed Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Richter's Transformation</condition>
  <arm_group>
    <arm_group_label>Disease-specific cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered the oral triple-combination therapy, DTRM-555 (comprised of 200mg of DTRMWXHS-12, 5mg of everolimus and 2mg of pomalidomide), once-daily for 21 consecutive days every 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTRM-555</intervention_name>
    <description>Oral once-daily administration</description>
    <arm_group_label>Disease-specific cohorts</arm_group_label>
    <other_name>DTRMWXHS-12</other_name>
    <other_name>everolimus</other_name>
    <other_name>pomalidomide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must provide written informed consent.&#xD;
&#xD;
          -  Patients with a diagnosis of R/R CLL or other B-cell neoplasms (i.e., ABC DLBCL, GCB&#xD;
             DLBCL, Richter's transformation and tFL) who have no available approved therapies, or&#xD;
             patients with a diagnosis of non-Hodgkin's lymphoma, which has relapsed and/or is&#xD;
             refractory to standard therapy.&#xD;
&#xD;
             a. Patients with R/R CLL must have been exposed to Bruton's tyrosine kinase (BTK) or&#xD;
             B-Cell CLL/Lymphoma 2 (BCL2) inhibitor-based therapy in prior lines of therapy but&#xD;
             must not have known Cys481 resistance mutation prior to study enrollment.&#xD;
&#xD;
          -  Age â‰¥ 18 years.&#xD;
&#xD;
          -  Life expectancy greater than 12 weeks.&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 or 1.&#xD;
&#xD;
          -  Ability to swallow and retain capsules and/or tablets.&#xD;
&#xD;
          -  Absence of uncontrolled intercurrent illnesses, including uncontrolled infections,&#xD;
             cardiac conditions, or other organ dysfunctions.&#xD;
&#xD;
          -  If the patient consents to an optional tumor biopsy, he/she must have a tumor that can&#xD;
             be safely biopsied and undergo a baseline tumor biopsy procedure, or be willing to&#xD;
             provide available archival tissue collected within 6 months of signing the Informed&#xD;
             Consent Form (ICF), and one post-Cycle 1 treatment biopsy.&#xD;
&#xD;
          -  Patients must have at least one target lesion according to Lugano Classification.&#xD;
             Patients with R/R CLL are exempt from this requirement.&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative serum or urine pregnancy test.&#xD;
&#xD;
          -  Women of child-bearing potential must agree to use 2 reliable methods of contraception&#xD;
             beginning 4 weeks prior to the initiation of treatment, during therapy, and for at&#xD;
             least 4 weeks after the last drug administration.&#xD;
&#xD;
          -  Men must agree to use a latex or synthetic condom during sexual contact with a&#xD;
             pregnant female or a female of child-bearing potential, for the duration of the study&#xD;
             and for at least 4 weeks after the last drug administration, even if they have&#xD;
             undergone a successful vasectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received prior systemic anticancer treatment within the following time frames:&#xD;
&#xD;
               1. Chemotherapy, immunotherapy, radiotherapy or any other investigational therapy&#xD;
                  within 21 days prior to starting study treatment.&#xD;
&#xD;
               2. Targeted therapies within 5 biological half-lives prior to starting study&#xD;
                  treatment.&#xD;
&#xD;
          -  Patients with active infections requiring therapy are not eligible for entry into the&#xD;
             study until resolution of the infection; however, patients on prophylactic&#xD;
             antibiotics, antifungals or antivirals are eligible for entry into the study.&#xD;
&#xD;
          -  Pregnant or lactating individuals.&#xD;
&#xD;
          -  Impaired hepatic or renal function as demonstrated by any of the following laboratory&#xD;
             values:&#xD;
&#xD;
               1. Aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 2.5 x upper limit of&#xD;
                  normal (ULN); for patients with liver involvement, &gt; 5 x ULN&#xD;
&#xD;
               2. Total bilirubin &gt; 1.5 x ULN (Patients with a history of Gilbert's syndrome may&#xD;
                  participate if total bilirubin is less than or equal to 3 x ULN and the AST/ALT&#xD;
                  and alkaline phosphatase meet the protocol-specified levels for eligibility)&#xD;
&#xD;
               3. Alkaline phosphatase &gt; 2.5 x ULN&#xD;
&#xD;
               4. Glomerular filtration rate &lt; 50 mL/min, as assessed using the standard&#xD;
                  methodology at the investigating center (i.e., Cockcroft-Gault), or serum&#xD;
                  creatinine &gt; 1.5 x ULN&#xD;
&#xD;
          -  International normalized ratio (INR) &gt; 1.5 or other evidence of impaired hepatic&#xD;
             synthesis function.&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1.0 x 109/L or platelets &lt; 100 x 109/L, unless due to&#xD;
             disease-related bone marrow impairment as confirmed by bone marrow biopsy during&#xD;
             screening or due to standard of care treatment within 2 months prior to signing of&#xD;
             informed consent. Patients with bone marrow impairment will be excluded if their&#xD;
             absolute neutrophil count (ANC) is &lt; 0.5 x 109/L and platelets &lt; 50 x 109/L.&#xD;
&#xD;
          -  Previous allogeneic bone marrow transplant is restricted, unless transplant was&#xD;
             greater than 3 months prior and there is no evidence of acute or chronic graft versus&#xD;
             host disease.&#xD;
&#xD;
          -  Central nervous system involvement with malignancy.&#xD;
&#xD;
          -  Patients who have poorly controlled diabetes mellitus or whose glucose values cannot&#xD;
             be controlled with medical treatment.&#xD;
&#xD;
          -  Current malignancies of another type, with the exception of adequately treated in situ&#xD;
             cervical cancer and basal cell skin cancer, squamous cell carcinoma of the skin or&#xD;
             other malignancies with no evidence of disease for 2 years or more.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus&#xD;
             (HCV) or hepatitis B virus (HBV). Subjects who are positive for hepatitis B core&#xD;
             antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative&#xD;
             polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive&#xD;
             will be excluded.&#xD;
&#xD;
          -  Documented or known bleeding disorder.&#xD;
&#xD;
          -  Requirement for anticoagulation treatment that increases INR or activated partial&#xD;
             thromboplastin time above the normal range (low molecular weight heparin and heparin&#xD;
             line flush allowed).&#xD;
&#xD;
          -  Patients requiring the use of strong CYP3A4, CYP1A2, or P-gp inhibitors.&#xD;
&#xD;
          -  Patients with a significant cardiovascular disease or condition, including:&#xD;
&#xD;
               1. myocardial infarction within 6 months of study entry,&#xD;
&#xD;
               2. New York Heart Association Class III or IV heart failure,&#xD;
&#xD;
               3. uncontrolled dysrhythmias or poorly controlled angina,&#xD;
&#xD;
               4. history of serious ventricular arrhythmia (ventricular fibrillation or&#xD;
                  ventricular tachycardia, â‰¥ 3 beats in a row) and/or risk factors (e.g., heart&#xD;
                  failure, hypokalemia, or family history of Long QT Syndrome),&#xD;
&#xD;
               5. baseline prolongation of QT/QTc interval (repeated demonstration of corrected QT&#xD;
                  interval (QTc) â‰¥ 450 msec for men and 470 msec for women), and&#xD;
&#xD;
               6. left ventricular ejection fraction (LVEF) &lt; 45% by multiple gated acquisition&#xD;
                  (MUGA) and /or echocardiogram (ECHO).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei He, PhD</last_name>
    <phone>(215) 337-3168</phone>
    <email>wei.he@dtrmbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Allison Rosenthal, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale - Smillow Cancer Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hematology Program</last_name>
      <phone>203-200-4363</phone>
    </contact>
    <investigator>
      <last_name>Scott Huntington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Han Tun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Wei Ding, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patient Access Services</last_name>
      <phone>800-525-2225</phone>
    </contact>
    <investigator>
      <last_name>Anthony Mato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duke Recruitment Innovation Center</last_name>
      <phone>919-681-5698</phone>
    </contact>
    <investigator>
      <last_name>Danielle Brander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abramson Center Clinical Trial Information Center</last_name>
      <phone>855-216-0098</phone>
    </contact>
    <investigator>
      <last_name>Stephen J Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-Cell Lymphoma</keyword>
  <keyword>Diffuse Large B Cell Lymphoma</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Leukemia</keyword>
  <keyword>B-Cell Leukemia</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Lymphatic Diseases</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Malignant Lymphoma</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Tyrosine Protein Kinase</keyword>
  <keyword>Bruton's Tyrosine Kinase Inhibitor</keyword>
  <keyword>Pomalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

